Document Detail

Maternal serum heme-oxygenase-1 (HO-1) concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus.
Jump to Full Text
MedLine Citation:
PMID:  23139759     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Heme oxygenase-1 (HO-1) concentrations have been recently reported to be elevated in impaired glucose tolerance and type 2 diabetes mellitus (T2DM). However, no study has examined the association between HO-1 concentrations and gestational diabetes mellitus (GDM).
METHODS: In a case-control study, nested within a prospective cohort of pregnant women (186 GDM cases and 191 women who remained eu-glycemic through pregnancy), we assessed the association of maternal serum HO-1 concentrations, measured in samples collected at 16 weeks gestation, on average, with subsequent risk of GDM. Maternal serum HO-1 concentrations were determined using ELISA. We fitted multivariate logistic regression models to derive estimates of odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: Median serum HO-1 concentrations in early pregnancy were lower in women who subsequently developed GDM compared with those who did not (1.60 vs. 1.80 ng/mL, p-value=0.002). After adjusting for maternal age, race, family history of T2DM and pre-pregnancy body mass index, women with HO-1 ≥ 3.05 ng/mL (highest decile) experienced a 74% reduction of GDM risk (95% CI; 0.09-0.77) compared with women whose concentrations were<1.23 ng/mL (lowest quartile).
CONCLUSION: Serum HO-1 concentrations were inversely associated with subsequent GDM risk. These findings underscore the role of oxidative stress in the pathogenesis of GDM. Additional studies are warranted to confirm the clinical utility of serum HO-1 in diagnosis of GDM, particularly in the early pregnancy.
Chunfang Qiu; Karin Hevner; Daniel A Enquobahrie; Michelle A Williams
Related Documents :
3595909 - Tubal anastomosis: pregnancy success following reversal of falope ring or monopolar cau...
552769 - The treatment with 2-brom-alfa ergocriptine in the syndrome amenorrhea-galactorrhea.
7959329 - Tubal anastomosis in the rat using the tissue adhesive cyanoacrylate (histoacryl).
2903089 - Clearance pattern of maternal serum pregnancy specific beta 1-glycoprotein after treatm...
7117569 - Conservative surgery for tubal pregnancy.
3177549 - Histopathologic study of ampullary and isthmic tubal ectopic pregnancy.
9822979 - Outcome of ivf in patients with endometriosis in comparison with tubal-factor infertility.
25267089 - Pregnancy outcomes in patients with systemic lupus erythematosus: a retrospective revie...
9431569 - A follow-up study of environmental and biologic determinants of fertility among 430 dan...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-11-06
Journal Detail:
Title:  PloS one     Volume:  7     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2012  
Date Detail:
Created Date:  2012-11-09     Completed Date:  2013-04-23     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e48060     Citation Subset:  IM    
Center for Perinatal Studies, Swedish Medical Center, Seattle, Washington, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
Case-Control Studies
Confidence Intervals
Diabetes, Gestational / blood*,  enzymology*
Heme Oxygenase-1 / blood*
Odds Ratio
Statistics, Nonparametric
Grant Support
Reg. No./Substance:
0/Biological Markers; EC protein, human; EC Oxygenase-1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2012 Qiu et al
Received Day: 18 Month: 7 Year: 2012
Accepted Day: 19 Month: 9 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 6 Month: 11 Year: 2012
Volume: 7 Issue: 11
E-location ID: e48060
PubMed Id: 23139759
ID: 3490957
Publisher Id: PONE-D-12-21281
DOI: 10.1371/journal.pone.0048060

Maternal Serum Heme-Oxygenase-1 (HO-1) Concentrations in Early Pregnancy and Subsequent Risk of Gestational Diabetes Mellitus Alternate Title:Early Pregnancy Serum HO-1 Levels and GDM Risk
Chunfang Qiu1*
Karin Hevner1
Daniel A. Enquobahrie12
Michelle A. Williams13
Ana Claudia Zenclussenedit1 Role: Editor
1Center for Perinatal Studies, Swedish Medical Center, Seattle, Washington, United States of America
2Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, United States of America
3Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
Medical Faculty, Otto-von-Guericke University Magdeburg, Germany
Correspondence: * E-mail:
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: CFQ MAW. Performed the experiments: KH. Analyzed the data: CFQ MAW. Contributed reagents/materials/analysis tools: MAW KH. Wrote the paper: CFQ KH DAE MAW.


Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications affecting approximately 7% of all pregnancies and up to 14% of pregnancies in high-risk populations [1]. GDM is manifested by pregnancy –induced insulin resistance and a relative impairment in insulin secretion [2]. Women with a history of GDM have a considerably elevated risk of developing impaired glucose tolerance or type 2 diabetes mellitus (T2DM) in the years following pregnancy. For instance, the cumulative incidence of developing T2DM later in life has been reported to range from 22% to 60% [3][5] among women with a prior history of GDM. Although the pathogenesis of GDM remains unclear, enhanced oxidative stress in the form of lipid peroxidation [6] and DNA oxidative damage [7] in GDM have been noted in previous studies. Moreover, results from other studies have indicated that chronic systemic inflammation [8], elevated leptin [9], reductions in adiponectin [10] and endothelial dysfunction [11] are important metabolic derangements that precede the clinical diagnosis of GDM.

The enzyme heme oxygenase (HO) has been implicated in several physiological functions throughout the body, including the control of vascular tone and regulation of the inflammatory and apoptotic cascades as well as contributing to the antioxidant capacity in several organ systems [12]. These various biological functions attributed to HO are mediated via the catalytic products of heme degradation, namely carbon monoxide (CO), biliverdin-derived bilirubin, and free iron (Fe2+) [13]. The expression of inducible isoform HO-1 is highly responsive to a broad spectrum of chemical and physical stress agents, such as hydrogen peroxide, hypoxia, hyperoxia, pro-inflammatory cytokines and heme itself. Consequently, HO-1 is regarded as a stress protein [12]. The role of HO-1 in the pathogenesis of T2DM and its complications has been investigated by several research teams. Of note, several investigators have assessed the influence of total HO activity and blood concentrations on neovascularization [14]. For example, the up regulation of HO-1 gene expression and increased HO-1 enzyme activity are thought to play protective roles against the development of diabetic complications [14]. In animal studies, investigators have shown that elevated HO-1 gene expression in pancreatic islet cells exposed to elevated glucose concentrations [15]. Of note, other investigators have shown that chronic hyperglycemia in a rat model, where hyperglycemia was induced by partially pancreatectomy, resulted in decreased HO-1 gene expressions in islets cells with increasing duration of hyperglycemia [16]. Recently, elevated circulating plasma HO-1 concentrations have been observed in patients with impaired glucose regulation [17] and T2DM [18] in a Chinese population. However, these cross- sectional, case-control study designs do not allow investigators to clarify whether alterations in HO-1 concentrations are a cause or consequence of the impaired glucose tolerance or T2DM.

To our knowledge, no previous study has examined the extent to which, if at all, maternal serum HO-1 concentrations in early pregnancy may be related with incident GDM. On the basis of an emerging literature documenting associations of HO-1 with hyperglycemia, impaired glucose tolerance and T2DM, we used serum specimens gathered as part of a prospective cohort study of women receiving prenatal care before 20 weeks gestation to examine the association between early-pregnancy serum HO-1 concentrations and subsequent risk of GDM.

Materials and Methods
Study Population

This nested case-control study was based on the Omega study, a prospective cohort study of risk factors of pregnancy complications [19]. In this cohort, participants were recruited from women attending prenatal care at clinics affiliated with Swedish Medical Center in Seattle and Tacoma General Hospital in Tacoma, Washington. Women were ineligible if they initiated prenatal care after 20 weeks gestation, were younger than 18 years of age, did not speak and read English, did not plan to carry the pregnancy to term, or did not plan to deliver at either of the two research hospitals. Participants completed a questionnaire administered in English by a trained interviewer at or near enrollment. These questionnaires were used to gather information on socio-demographic, anthropometric, and behavioral characteristics and reproductive and medical histories. After delivery, maternal and infant medical records were abstracted for information on the course and outcomes of pregnancy. The study protocol was approved by Institutional Review Boards of Swedish Medical Center and Tacoma General Hospital according to the declaration of Helsinki and written informed consent was obtained from all individuals. Between 1996 and 2006, 5,063 eligible women were approached and 4,000 (approximately 79%) agreed to participate. A total of 3,886 pregnant women provided blood samples and completed interviews.

From structured questionnaires and medical records, we obtained information of covariates including maternal age, educational attainment, height, pre-pregnancy weight, reproductive and medical histories, and medical histories of first-degree family members. We also collected information on annual household income and maternal smoking before and during pregnancy. Pre-pregnancy body mass index (BMI) was calculated as pre-pregnancy weight in kilograms divided by height in meters squared. Maternal medical records were reviewed to collect detailed medical and clinical information including laboratory results such as glucose concentrations from screening test and first trimester hematocrit concentrations. We used the food frequency questionnaire (FFQ) from the Women’s Health Initiative Clinical Trial [20] to assess maternal dietary intake during the three-month period that started before conception and covered the first trimester. Participants completed FFQs at an average of 15.3 weeks gestation. Dietary intake values of nutrients, and minerals including heme iron [21] were estimated using food composition tables from the University of Minnesota Nutrition Coding Center nutrient database (Nutrition Coordinating Center, Minneapolis, MN).

Maternal non-fasting blood samples, collected in 10 mL Vacutainer tubes at 16 weeks gestation, on average, were protected from ultraviolet light, kept on wet ice and processed within 20 min of blood collection. Serum decanted into cryovials was frozen at −80°C until analysis. Serum HO-1 concentrations were determined by HO-1 ELISA kits (Enzo Life Sciences Plymouth Meeting, PA) in accordance with the manufacturer’s protocol. The intra- and inter-assay coefficients of variations of HO-1 kit had been determined to be<10%. All assays were performed without knowledge of pregnancy outcome.

In our study settings, according to the recommendations from the American Diabetes Association (ADA) [22], pregnant women were screened at 24–28 weeks gestation using a 50 g 1-hour oral glucose challenge test. Those patients who failed this screening test (glucose ≥7.8 mmol/L or 140 mg/dL) were then followed-up within 1–2 weeks with a 100 g, 3-h oral glucose tolerance test (OGTT). Women were diagnosed with GDM if two or more of the 100 gram OGTT glucose levels exceeded the following thresholds based on the ADA criteria: fasting ≥5.3 mmol/L (≥95 mg/dL); 1-hour ≥10.0 mmol/L (≥180 mg/dL); 2-hour ≥8.6 mmol/L (≥155 mg/dL); 3-hour ≥7.8 mmol/L (≥140 mg/dL) [22].

We identified and sampled all 191 women who developed GDM and randomly selected (N = 191) controls among women who did not develop GDM. There were 5 GDM cases with an inadequate volume of serum for laboratory testing, thus our final analytical study population included 186 GDM cases and 191 non-GDM controls.

Statistical Analysis

Because the distribution of serum HO-1 concentrations was not normally distributed (Skewness/Kurtosis tests for Normality was<0.01 in either GDM cases or controls), we tested differences in median serum HO-1 concentrations between cases and controls using the Mann-Whitney U test. Spearman correlation coefficients were examined between serum HO-1 concentrations with maternal characteristics, selected FFQ variables, plasma glucose concentrations after the 50-gram oral glucose challenge screening test, and first trimester hematocrit concentrations. First, we categorized serum HO-1 concentrations according to quartiles determined by the distribution among controls. We used logistic regression models to estimate odds ratios (OR) and 95% confidence interval (95% CI). We also explored the possibility of a nonlinear relation between HO-1 and GDM odds, using generalized additive logistic regression modeling procedures (GAM) [23]. S-Plus (version 6.1, release 2, Insightful Inc. Seattle, WA) was used for these analyses. We evaluated the covariates in Table 1 as potential confounders and included in the final model those that altered unadjusted ORs by 10% or more and a prior, including maternal age, race/ethnicity, family history of diabetes and pre-pregnancy body mass index. All analyses except the GAM procedure) were performed using Stata 9.0 (Stata, College Station, TX). All reported confidence intervals were calculated at the 95% level and all reported p-values are two-tailed.


Sociodemographic, medical, and behavioral characteristics of the study population, according to case status, are presented in Table 1. Early pregnancy serum HO-1 concentrations were significantly lower among women who developed GDM as compared with women who did not (median 1.60 vs. 1.80 ng/mL, respectively, p-value = 0.002) (Table 1 and Figure 1).

Among controls, serum HO-1 concentrations were inversely correlated with dietary heme iron intake and red/processed meat intake (Spearman ρ = –0.27 with p-value<0.001; ρ = –0.18 with p-value = 0.02, respectively) (Table 2). Serum HO-1 was also inversely correlated with post-load plasma glucose concentrations and first trimester hematocrit levels within the control group (Spearman ρ = –0.16 with p-value = 0.03; ρ = –0.18 with p-value = 0.02, respectively). However, similar correlations were not observed among GDM cases.

The unadjusted ORs of GDM decreased across increasing quartiles of maternal serum HO-1 (p-value for linear trend = 0.02) (Table 3). After adjustment for maternal age, non-white race, family history of diabetes and pre-pregnancy BMI, early-pregnancy HO-1 concentrations were inversely associated with GDM risk, though the association was no longer statistically significant. Of note, the adjusted OR for the highest vs. lowest quartile for HO-1 concentrations was 0.58 (95% CI 0.30–1.11). We also compared women with the highest concentrations of serum HO-1 concentrations (i.e., those with values in the upper decile of the distribution of H0-1 concentrations among controls) to these women with the lowest HO-1 concentrations (i.e., women in the lowest quartile). After adjusting for confounders, extremely high HO-1 (top decile>3.05 ng/mL) was associated with a 74% decreased odds of GDM (OR = 0.26; 95% CI 0.09–0.77). This finding corresponds to the observation from our flexible dose response model (i.e., from GAM models) and related splines (Figure 2), where we noted an inverse association of GDM risk with increasing HO-1 concentrations, particularly when concentrations exceeded 3 ng/mL (Figure 2).


To the best of our knowledge, the current study is the first to examine the relationship between circulating HO-1 concentrations and GDM risk. Furthermore, our study is particularly significant because the relationship was assessed prospectively. We found that an elevated serum HO-1 concentration in early pregnancy is associated with decreased risk of subsequent GDM.

As an inducible stress protein, HO-1 is widely accepted to be a highly sensitive and reliable marker of oxidative stress [12]. Up-regulation of HO-1 protein is thought to represent an attempt to minimize cellular injury. Notably, cells isolated from HO-1 knock-out mice demonstrate lower resistance to oxidative stress [24]. And it was further confirmed in a typical two-allele HO-1 deficiency human case where enhanced endothelial injury was observed following oxidative stress [25]. A recent report also noted a parallel increase in HO-1 protein levels, HO activity, and the levels of serum adiponectin, a protein hormone that is known to modulate a number of metabolic processes, including improved insulin sensitivity and reduced adiposity [26]. The report that HO-1 regulates mitochondrial transport carriers and function [27] suggests that HO-1, by activating Bcl-2 and Bcl-xL, prevents cytochrome c release and activation of caspases. Collectively, these results suggest that it may be possible to favorably modulate the balance between pro- and anti-apoptotic mechanisms. The HO-1 system has been shown to regulate T-cell proliferation and immune response [28], [29]. A reduction in antioxidant reserves has been related to endothelial cell dysfunction in diabetes [30]. Increased levels of HO-1, through gene transfer in hyperglycemic rats, resulted in a decrease of endothelial cell sloughing [31]. Delivery of the human HO-1 gene to endothelial cells attenuated glucose-mediated oxidative stress, DNA damage, and cell death [32].

Few studies reported that circulating levels of HO-1 were increased in glucose intolerance [17] or T2DM [18] as well as other chronic diseases related to oxidative stress such as silicosis [33], secondary hemophagocytic syndrome (HPS) or adult-onset Still’s disease [34] and Parkinson’s disease [35]. However, Mateo reported that median serum levels of HO-1 did not differ significantly between Alzheimer’s disease patients and controls [35]. Most of the studies were cross-sectional. For example, our results were different from what Bao observed in patients with impaired glucose regulation or T2DM from 2 case control studies. Bao and his colleague [17] found plasma HO-1 concentration was significantly increased among non-diabetic individuals with impaired-glucose-regulation compared with healthy controls (1.34 (0.81–2.29) ng/mL versus 0.98 (0.56–1.55) ng/mL, P<0.001). In an earlier study, Bao reported that plasma HO-1 concentrations were significantly increased in newly diagnosed-T2DM cases compared to controls (median (IQR): 2.42 (1.39–3.90) ng/mL in cases vs. 1.11 (0.63–2.06) ng/mL in controls, P<0.001). The ORs for incident T2DM in the highest quartile of plasma HO-1 concentrations, compared with the lowest, was 8.23 (95% CI 5.55–12.21; P for trend<0.001) [18]. It needs to be noted, however, that these studies assessed serum HO-1 after or at the time of the clinical diagnosis of T2DM. Consequently, given the cross sectional nature of their study design, it is not possible to clarify the temporal relationship of altered HO-1 synthesis and release with the development of T2DM.

In the current study, we observed that increased serum HO-1 concentrations were associated with low dietary heme iron intake/red meat consumption among women who were euglycemic throughout pregnancy; however, this negative correlation was disrupted in women who subsequently developed GDM. High levels of dietary heme iron intake during the pre-pregnancy, preconceptionally and early pregnancy periods are associated to increased GDM risk [36]. In our study, those who developed GDM had higher heme iron intake/red meat consumption (heme iron: 0.83 vs. 0.76 mg/day; red meat: 0.64 vs. 0.58 servings/day) which is consistent to previous report. And, further adjusting for the above factors in the logistic regression model did not change our estimates materially (data not shown).

Our study has several strengths. First, determination of HO-1 concentrations using serum collected in early pregnancy served to define a relationship between the biomarker and subsequent risk of GDM. Second, the high follow-up rate (>95%) of women enrolled in our study minimized possible selection bias. However, several limitations also merit discussion and consideration. First, a single measurement of serum HO-1 concentrations is not likely to provide a time-integrated measure of maternal circulating HO-1 levels during the entire pregnancy. Thus, longitudinal studies with serial measurements of circulating HO1 concentrations along with indices of insulin sensitivity and secretion across gestation are needed to elucidate the mechanisms and pathophysiological consequences of maternal oxidative stress during pregnancy. Second, as with all observational studies, although we adjusted for known and suspected confounders, we cannot exclude the possibility of residual confounding from unmeasured covariates. Third, universal glucose tolerance testing in early pregnancy is not part of the standard obstetric care. Hence, we cannot exclude the possibility that some subjects in our study had undiagnosed pre-gestational diabetes. However, over 95% of study subjects reported having regular medical exams within a 24-month period before the index pregnancy; and the cumulative incidence of GDM in our study cohort is consistent with observations in other settings [1]. Fourth, the source of the circulating HO-1 still remains uncertain, more careful metabolic studies to help isolate the source(s) of HO-1 are warranted. Finally, the generalizability of our finding is limited to a largely non-Hispanic White, well -educated obstetric population.

In summary, this report extends the current literature by documenting a relation between early pregnancy serum HO-1 concentrations and GDM risk. Large-scale longitudinal studies with multiple point measurements throughout pregnancy, however, are warranted to further exam the extent to which early pregnancy circulating HO-1 concentrations and/or the change of HO-1 concentration during pregnancy might be used as a risk marker for GDM.

1. American Diabetes Association (2011) III. Detection and Diagnosis of GDM. Diabetes Care (suppl 1): S15.
2. Buchanan TA,, Xiang A,, Kjos SL,, Watanabe R, (Year: 2007) What is gestational diabetes?Diabetes Care 200730: S105–S111
3. Damm P, (Year: 1998) Gestational diabetes mellitus and subsequent development of overt diabetes mellitus. Danish Med Bulletin45: 495–509
4. Engeland A,, Bjørge T,, Daltveit AK,, Skurtveit S,, Vangen S,, et al. (Year: 2011) Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway. Eur J Epidemiol26: 157–16321298469
5. Mukerji G,, Chiu M,, Shah BR, (Year: 2012) Impact of gestational diabetes on the risk of diabetes following pregnancy among Chinese and South Asian women. Diabetologia55: 2148–215322526611
6. Suhail M,, Patil S,, Khan S,, Siddiqui S, (Year: 2010) Antioxidant Vitamins and Lipoperoxidation in Non-pregnant, Pregnant, and Gestational Diabetic Women: Erythrocytes Osmotic Fragility Profiles. J Clin Med Res2: 266–27322043260
7. Qiu C,, Hevner K,, Abetew D,, Enquobahrie DA,, Williams MA, (Year: 2011) Oxidative DNA damage in early pregnancy and risk of gestational diabetes mellitus: A pilot study. Clin Biochem44: 804–80821601569
8. Chen X,, Scholl TO,, Stein TP, (Year: 2006) Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: The Camden study. Diabetes Care29: 1077–108216644640
9. Qiu C,, Williams MA,, Vadachkoria S,, Frederick IO,, Luthy DA, (Year: 2004) Increased maternal plasma leptin in early pregnancy and risk of gestational diabetes mellitus. Obstet Gynecol103: 519–52514990416
10. Williams MA,, Qiu C,, Muy-Rivera M,, Vadachkoria S,, Song T,, et al. (Year: 2004) Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. J Clin Endocrinol Metab89: 2306–231115126557
11. Paradisi G,, Biaggi A,, Ferrazzani S,, De Carolis S,, Caruso A, (Year: 2002) Abnormal carbohydrate metabolism during pregnancy: association with endothelial dysfunction. Diabetes Care25: 560–56411874947
12. Abraham NG,, Kappas A, (Year: 2008) Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev60: 79–12718323402
13. Tenhunen R,, Marver HS,, Schmid R, (Year: 1969) Microsomal heme oxygenase: Characterization of the enzyme. J Biol Chem244: 6388–63944390967
14. Grochot-Przeczek A,, Dulak J,, Jozkowicz A, (Year: 2010) Heme oxygenase-1 in neovascularisation: A diabetic perspective. Thromb Haemost104: 424–43120539916
15. Jonas JC,, Guiot Y,, Rahier J,, Henquin JC, (Year: 2003) Haeme-oxygenase 1 expression in rat pancreatic beta cells is stimulated by supraphysiological glucose concentrations and by cyclic AMP. Diabetologia46: 1234–124412898011
16. Laybutt DR,, Glandt M,, Xu G,, Ahn YB,, Trivedi N,, et al. (Year: 2003) Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem278: 2997–300512438314
17. Bao W,, Rong S,, Zhang M,, Yu X,, Zhao Y,, et al. (Year: 2012) Plasma heme oxygenase-1 concentration in relation to impaired glucose regulation in a non-diabetic Chinese population. PLoS One7: e3222322427825
18. Bao W,, Song F,, Li X,, Rong S,, Yang W,, et al. (Year: 2010) Plasma heme oxygenase-1 concentration is elevated in individuals with type 2 diabetes mellitus. PLoS One5(8): e1237120811623
19. Qiu C,, Zhang C,, Gelaye B,, Enquobahrie DA,, Frederick IO,, et al. (Year: 2011) Gestational diabetes mellitus in relation to maternal dietary heme iron and nonheme iron intake. Diabetes Care34: 1564–156921709295
20. Patterson RE,, Kristal AR,, Tinker LF,, Carter RA,, Bolton MP,, et al. (Year: 1999) Measurement characteristics of the Women’s Health Initiative food frequency questionnaire. Ann Epidemiol9: 178–18710192650
21. Office of Dietary Supplements, National Institutes of Health. Dietary Supplement Fact Sheet: Iron [Internet]. Available from Accessed 08 May 2012.
22. American Diabetes Association (2004). Gestational diabetes mellitus. Diabetes Care (Suppl. 1): S88–S90.
23. Hastie TJ, Tibshirani RJ (1990). Generalized Additive Models London: Chapman-Hall.
24. Poss KD,, Tonegawa S, (Year: 1997) Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA94: 10925–109309380736
25. Yachie A,, Niida Y,, Wada T,, Igarashi N,, Kaneda H,, et al. (Year: 1999) Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest103: 129–1359884342
26. Li M,, Kim DH,, Tsenovoy PL,, Peterson SJ,, Rezzani R,, et al. (Year: 2000) Hemeoxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function. FASEB J14: 208–21910627295
27. Di Noia MA,, Van Driesche S,, Palmieri F,, Yang LM,, Quan S,, et al. (Year: 2006) Heme oxygenase-1 enhances renal mitochondrial transport carriers and cytochrome C oxidase activity in experimental diabetes. J Biol Chem281: 15687–1569316595661
28. Pae HO,, Oh GS,, Choi BM,, Chae SC,, Chung HT, (Year: 2003) Differential expressions of heme oxygenase-1 gene in CD25− and CD25+subsets of human CD4+T cells. Biochem Biophys Res Commun306: 701–70512810075
29. Chen S,, Kapturczak MH,, Wasserfall C,, Glushakova OY,, Campbell-Thompson M,, et al. (Year: 2005) Interleukin 10 attenuates neointimal proliferation and inflammation in aortic allografts by a heme oxygenase-dependent pathway. Proc Natl Acad Sci USA102: 7251–725615878989
30. Baynes JW, (Year: 1991) Role of oxidative stress in development of complications in diabetes. Diabetes40: 405–4122010041
31. Abraham NG,, Rezzani R,, Rodella L,, Kruger A,, Taller D,, et al. (Year: 2004) Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. Am J Physiol Heart Circ Physiol287: H2468–247715284058
32. Sacerdoti D,, Olszanecki R,, Li VG,, Colombrita C,, Scapagnini G,, et al. (Year: 2005) Heme oxygenase overexpression attenuates glucose-mediated oxidative stress in quiescent cell phase: linking heme to hyperglycemia complications. Curr Neurovasc Res2103–11116181102
33. Sato T,, Takeno M,, Honma K,, Yamauchi H,, Saito Y,, et al. (Year: 2006) Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-induced lung injury. Am J Respir Crit Care Med174: 906–91416858012
34. Miyazaki T,, Kirino Y,, Takeno M,, Hama M,, Ushihama A,, et al. (Year: 2010) Serum HO-1 is useful to make differential diagnosis of secondary hemophagocytic syndrome from other similar hematological conditions. Int J Hematol91: 229–23720091384
35. Mateo I,, Infante J,, Sánchez-Juan P,, García-Gorostiaga I,, Rodríguez-Rodríguez E,, et al. (Year: 2010) Serum heme oxygenase-1 levels are increased in Parkinson’s disease but not in Alzheimer’s disease. Acta Neurol Scand121: 136–13819785642
36. Bowers K,, Yeung E,, Williams MA,, Qi L,, Tobias DK,, et al. (Year: 2011) A prospective study of prepregnancy dietary iron intake and risk for gestational diabetes mellitus. Diabetes Care34: 1557–156321709294


[Figure ID: pone-0048060-g001]
doi: 10.1371/journal.pone.0048060.g001.
Figure 1  The dotplot of serum HO-1 concentrations according to GDM case-control status with median (+++), the lowest, or the highest quartile bar lines (---) indicated.

[Figure ID: pone-0048060-g002]
doi: 10.1371/journal.pone.0048060.g002.
Figure 2  Relation between maternal serum HO-1 concentrations and the adjusted relative odds of gestational diabetes mellitus (GDM) (solid line), with 95% CI (dotted lines).

The vertical bars along the serum HO-1 concentrations axis indicate distribution of study subjects. The estimates were adjusted by maternal age, race/ethnicity, family history of diabetes and pre-pregnancy body mass index. (Excluded 3 subjects with serum HO-1 measurements>4 ng/mL, all are non-GDM.).

[TableWrap ID: pone-0048060-t001] doi: 10.1371/journal.pone.0048060.t001.
Table 1  Characteristics of study participants according to gestational diabetes (GDM) case-control status.
GDM (n = 186) Controls (n = 191) P value
n % n %
Maternal age (years) 33.9±4.7 33.0±4.3 0.05
Maternal age (years)
<25 7 3.8 5 2.6 0.08
25–29 19 10.2 35 18.3
30–34 73 39.2 79 41.4
≥35 87 46.8 72 37.7
White 133 71.5 165 86.4 0.004
African American 5 2.7 3 1.6
Asian 33 17.7 14 7.3
Other 14 7.5 9 4.7
unknown 1 0.5 0 0.0
Maternal education<12 years 9 4.8 5 2.6 0.25
Nulliparous 104 55.9 107 56.0 0.98
Unmarried 31 16.7 28 14.7 0.59
Family History: Diabetes 59 31.7 29 15.2 <0.001
Family History: Hypertension 107 57.5 87 45.6 0.02
No Vitamin Intake in Pregnancy 3 1.6 5 2.6 0.72
Cigarette Smoking History
Never 142 76.3 141 73.8 0.26
Quit during pregnancy 30 16.1 41 21.5
Current 14 7.5 9 4.7
Inactive in Pregnancy 40 21.5 30 15.7 0.15
Pre-pregnancy BMI (kg/m2) 26.8±7.1 23.4±5.1 <0.001
Pre-pregnancy BMI (kg/m2)
<18.5 4 2.2 10 5.2 <0.001
18.5–24.9 91 48.9 132 69.1
25–29.9 51 27.4 39 20.4
≥30 40 21.5 10 5.2
Gestational Age at Delivery (weeks) 38.1±2.1 38.5±2.8 0.08
Infant Birthweight (kg) 3.40±0.63 3.41±0.65 0.97
GA at Blood Collection (weeks) 15.3±2.9 15.4±3.1 0.81
Hours from last meal to blood collection 2.76±2.36 2.72±2.24 0.84
Serum HO-1 (ng/mL), median [IQR] 1.60 [1.11–2.08] 1.80 [1.23–2.41] 0.002

1Mean ± SD (standard deviation).

[TableWrap ID: pone-0048060-t002] doi: 10.1371/journal.pone.0048060.t002.
Table 2  The Spearman correlation coefficients (CC) between serum HO-1 concentrations and other biomarkers as well as maternal characteristics.
Spearman CC (Non-Parametric Correlations) GDM(n = 186) Controls(n = 191)
ρ P-value ρ P-value
Maternal age (years) −0.12 0.12 −0.10 0.18
Maternal pre-pregnancy BMI (kg/m2) −0.11 0.15 −0.11 0.12
Maternal gestational age at blood collection (weeks) −0.08 0.28 −0.05 0.47
Time from last meal to blood collection (hours) 0.08 0.27 0.08 0.27
Gestational age at delivery (weeks) 0.05 0.51 −0.10 0.17
Infant birth weight (kg) 0.01 0.85 −0.04 0.54
Available valid FFQ (calories: 500–3500kcal/day) N = 155 N = 170
Total energy intake (kcal/day) −0.08 0.35 −0.05 0.53
Dietary heme iron intake (mg/day) −0.09 0.27 0.27 <0.001
Dietary nonheme iron intake (mg/day) −0.09 0.29 0.01 0.85
Dietary total iron intake (mg/day) −0.09 0.29 −0.03 0.74
Red/processed meat intake (serving/day) 0.03 0.72 0.18 0.02
Vegetable and fruit intake (servings/day) 0.009 0.91 −0.08 0.31
Dietary fiber intake (mg/day) −0.01 0.89 −0.05 0.53
Dietary soluble fiber intake (mg/day) 0.03 0.72 0.02 0.80
Dietary insoluble fiber intake (mg/day) −0.03 0.74 −0.07 0.36
Egg intake (egg/weeks) −0.14 0.10 −0.01 0.94
Cholesterol (mg/day) −0.12 0.14 −0.13 0.09
First trimester hematocrit (%) (n = 340 available) 0.05 0.54 0.18 0.02
Glucose concentrations after a 50 g oral glucose challenge (mg/dL) 0.08 0.30 0.16 0.03

[TableWrap ID: pone-0048060-t003] doi: 10.1371/journal.pone.0048060.t003.
Table 3  The odds ratio (ORs) and 95% confidence intervals (CI) of gestational diabetes mellitus (GDM) risk according to different levels of maternal serum HO-1 at early pregnancy.
Serum HO-1(ng/mL) GDM(n = 186) Controls(n = 191) UnadjustedOR (95%CI) Adjusted1OR (95%CI)
Quartile 1 (<1.23) 55 (29.6) 47 (24.6) 1.00 (referent) 1.00 (referent)
Quartile 2 (1.23–1.79) 60 (32.2) 48 (25.1) 1.07 (0.62–1.84) 1.15 (0.64–2.07)
Quartile 3 (1.80–2.40) 42 (22.6) 48 (24.1) 0.75 (0.42–1.32) 0.96 (0.51–1.80)
Quartile 4 (≥2.41) 29 (15.6) 48 (25.1) 0.52 (0.28–0.94) 0.58 (0.30–1.11)
P for trend 0.018 0.10
Quartile 1 (<1.23) 55 (29.6) 47 (24.6) 1.00 (referent) 1.00 (referent)
Upper Decile (≥3.05) 6 (3.2) 20 (10.5) 0.26 (0.10–0.69) 0.26 (0.09–0.77)

1OR and 95% CI adjusted for maternal age, race/ethnicity, family history of diabetes and pre-pregnancy body mass index.

Article Categories:
  • Research Article
Article Categories:
  • Medicine
    • Clinical Research Design
      • Survey Research
    • Endocrinology
      • Diabetic Endocrinology
        • Diabetes Mellitus Type 2
        • Gestational Diabetes
        • Insulin
    • Obstetrics and Gynecology
      • Pregnancy
        • Pregnancy Complications
    • Public Health
      • Health Screening
    • Women's Health

Previous Document:  Secondary sympatry caused by range expansion informs on the dynamics of microendemism in a biodivers...
Next Document:  Knockout of insulin-like growth factor-1 receptor impairs distal lung morphogenesis.